Massarweh A, Eliakim-Raz N, Stemmer A, et al. - In order to evaluate antibody responses to messenger RNA SARS-CoV-2 vaccines among patients with cancer vs healthy controls, researchers conducted a cohort study including 102 patients with cancer who were receiving active treatment and 78 healthy controls. Seropositivity was observed in 92 patients with cancer (90%) and 100% of the controls after the second messenger RNA BNT162b2 vaccine dose. Overall findings suggest a good response to messenger RNA SARS-CoV-2 vaccines among patients with cancer who are receiving active treatment and are at higher risk for severe COVID-19 disease and that vaccination of these patients should be seriously considered.